A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's

NCT03943264 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: XPro1595

Sponsor

Inmune Bio, Inc.

Collaborators

[object Object]